BIT C2 Diagnostics Discloses Challenges in Instrumentation Development & Manufacture in IVD Trade Article

Share Article

Two chief executives from BIT C2 Diagnostics (a BIT Company) from Montpellier, France, have authored a feature article entitled “The Challenges of Developing Hematology Instruments” for professional medical trade magazine, IVD Technology. A clinical analyzer developed by BIT C2 Diagnostics is pictured on the front cover of the publication.

Henri Champseix (Chief Technology Officer / Director of R&D) and Eric Jolain (Chief Operating Officer) of BIT C2 Diagnostics have been published in the January/February, 2012 issue of IVD Technology magazine, a medical trade publication which focuses on the latest technology in in-vitro diagnostics. BIT C2 Diagnostics is a clinical instrumentation developer / manufacturer, specializing in hematology analyzers used in clinical laboratories as well as in physicians‘ offices.

The article published by BIT C2 Diagnostics, entitled, ““The Challenges of Developing Hematology Instruments”, describes the internal mechanisms of a hematology instrument and the technology challenges presented by customers‘ demands for speed-to-market and cost efficiency. BIT C2 Diagnostics addresses such requirements, in part, with hematology
SMARTSOLUTIONS – the utilization of a library of foundation technology hardware and software that can be used by more than one instrument. By exploiting the fact that many instruments share the basic building blocks with regard to both hardware and software, a manufacturer can repurpose a foundation that is proven and validated and spend development dollars on the functionality or feature that makes the instrument unique. With the availability of a virtual library of basic, certified components that are scalable and updateable, platform technology has changed the way many IVD OEMs do business. Unlike others, BIT’s platforms are not limited to only one specific diagnostic process. Instead, they provide a much broader, horizontal and vertical approach for equipment of varying size, configuration, process / technology and diagnostics. This approach translates directly into significant product development savings. The entire article, “The Challenges of Developing Hematology Instruments”, is available for download at http://www.bit-instruments.com/download/IVD_Technology_Hematology_Instrumentation_Development_Article_Jan2012.pdf.

For over 35 years BIT Companies (http://www.BIT-companies.com) have provided services in the field of contract development and manufacturing as well as after-sales service for customers in the fields of medical, diagnostics, life science, and biotechnology. As a part of the financially strong Messer Group, BIT Companies provide their systems solutions worldwide and in compliance with ISO 13485 and 9001 standards. As registered contract service providers to the FDA, BIT Companies meet the stringent regulations with regard to medical and complex medical technical products while simultaneously adhering to predefined design-to-cost and time-to-market targets.

BIT Companies include BIT Medtech in San Diego, CA, USA; Source Scientific, LLC in Irvine, California, USA; BIT Analytical Instruments Ltd.in Ludlow, Massachusetts USA; BIT Analytical Instruments GmbH in Schwal-bach, Germany; BIT Technologies in Kunshan, China; BIT Japan Ltd. in Tokyo Japan; and BIT C2 Diagnostics in Montpellier, France.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brian Jarvis
Visit website